Safety and Prognostic Value of Vasodilator Stress Cardiovascular Magnetic Resonance in Patients With Heart Failure and Reduced Ejection Fraction
Patients with heart failure with reduced ejection fraction (HFrEF; heart failure with reduced left ventricular ejection fraction
Gespeichert in:
| Veröffentlicht in: | Circulation. Cardiovascular imaging 2020-09, Vol.13 (9), p.e010599-e010599 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e010599 |
|---|---|
| container_issue | 9 |
| container_start_page | e010599 |
| container_title | Circulation. Cardiovascular imaging |
| container_volume | 13 |
| creator | Pezel, Théo Sanguineti, Francesca Kinnel, Marine Landon, Valentin Bonnet, Guillaume Garot, Philippe Hovasse, Thomas Unterseeh, Thierry Champagne, Stéphane Louvard, Yves Claude Morice, Marie Garot, Jérôme |
| description | Patients with heart failure with reduced ejection fraction (HFrEF; heart failure with reduced left ventricular ejection fraction |
| doi_str_mv | 10.1161/CIRCIMAGING.120.010599 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1161_CIRCIMAGING_120_010599</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32873071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4046-73ce5eab399a97d8e2ae9ff8b2461e4c7007f83855d3607ef5339a89ac1dd9b83</originalsourceid><addsrcrecordid>eNpNkd1OGzEQha2qqFDaV0B-gU3H6_2xL9GKhEiEotCfy9XEniWmyxrZXhBv0UfuJqGIqzkX55yRvsPYmYCZEJX41izXzXJ1vlheL2YihxkIKLX-wE6ELvIMQMHHd_qYfY7xHqCSUKpP7FjmqpZQixP29xY7Si8cB8tvgr8bfEzO8F_Yj8R9N4noresx-cBvU6AYeYPBOv-E0Yw9Br7Cu4F2mTVFP-BgiLuB32ByNKTIf7u05ZeEIfE5un4MtP-1JjsasvzinkxyfuDzgHvxhR112Ef6-npP2c_5xY_mMrv6vlg251eZKaCosloaKgk3UmvUtVWUI-muU5u8qAQVpgaoOyVVWVpZQU1dKaVGpdEIa_VGyVNWHXpN8DEG6trH4B4wvLQC2h3i9h3idkLcHhBPwbND8HHcPJB9i_1nOhmKg-HZ94lC_NOPzxTaLWGftlOLlHWhVZZDDqABYFpot8w_HhSKtQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and Prognostic Value of Vasodilator Stress Cardiovascular Magnetic Resonance in Patients With Heart Failure and Reduced Ejection Fraction</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Pezel, Théo ; Sanguineti, Francesca ; Kinnel, Marine ; Landon, Valentin ; Bonnet, Guillaume ; Garot, Philippe ; Hovasse, Thomas ; Unterseeh, Thierry ; Champagne, Stéphane ; Louvard, Yves ; Claude Morice, Marie ; Garot, Jérôme</creator><creatorcontrib>Pezel, Théo ; Sanguineti, Francesca ; Kinnel, Marine ; Landon, Valentin ; Bonnet, Guillaume ; Garot, Philippe ; Hovasse, Thomas ; Unterseeh, Thierry ; Champagne, Stéphane ; Louvard, Yves ; Claude Morice, Marie ; Garot, Jérôme</creatorcontrib><description>Patients with heart failure with reduced ejection fraction (HFrEF; heart failure with reduced left ventricular ejection fraction <40%) referred for stress cardiovascular magnetic resonance (CMR) may have a less optimal hemodynamic response to intravenous vasodilator. The aim was to assess the prognostic value of vasodilator stress perfusion CMR in patients with HFrEF.
Between 2008 and 2018, consecutive patients with HFrEF defined by left ventricular ejection fraction <40% prospectively referred for vasodilator stress perfusion CMR were followed for the occurrence of major adverse cardiovascular events (MACE), defined by cardiovascular death or nonfatal myocardial infarction. Univariable and multivariable Cox regressions were performed to determine the prognostic value of inducible ischemia or late gadolinium enhancement by CMR.
Of 1053 patients with HFrEF (65±11 years, median [interquartile range] left ventricular ejection fraction 38.7% [37.2-39.0]), 1018 (97%) completed the CMR protocol and 950 (93%) completed the follow-up (median [interquartile range], 5.6 [3.6-7.3] years); 117 experienced a MACE (12.3%). Stress CMR was well tolerated without any adverse events. Patients without ischemia or late gadolinium enhancement experienced a lower annual event rate of MACE (1.8%) than those with both ischemia and late gadolinium enhancement (12.0%;
<0.001). Using Kaplan-Meier analysis, inducible ischemia and late gadolinium enhancement were significantly associated with the occurrence of MACE (hazard ratio, 2.46 [95% CI, 1.69-3.60]; and hazard ratio, 2.92 [95% CI, 1.77-4.83], respectively, both
<0.001). In multivariable Cox regression, inducible ischemia was an independent predictor of a higher incidence of MACE (hazard ratio, 2.26 [95% CI, 1.52-3.35];
<0.001).
Stress CMR is safe and has a good discriminative prognostic value to predict the occurrence of MACE in patients with HFrEF.</description><identifier>ISSN: 1942-0080</identifier><identifier>ISSN: 1941-9651</identifier><identifier>EISSN: 1942-0080</identifier><identifier>DOI: 10.1161/CIRCIMAGING.120.010599</identifier><identifier>PMID: 32873071</identifier><language>eng</language><publisher>United States: American Heart Association, Inc</publisher><subject>Aged ; Contrast Media ; Dipyridamole - administration & dosage ; Dipyridamole - adverse effects ; Female ; Heart Failure - complications ; Heart Failure - diagnostic imaging ; Heart Failure - mortality ; Heart Failure - physiopathology ; Humans ; Infusions, Intravenous ; Longitudinal Studies ; Magnetic Resonance Imaging, Cine - adverse effects ; Male ; Meglumine ; Middle Aged ; Myocardial Infarction - etiology ; Myocardial Perfusion Imaging - adverse effects ; Organometallic Compounds ; Predictive Value of Tests ; Prognosis ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Stroke Volume ; Time Factors ; Vasodilator Agents - administration & dosage ; Vasodilator Agents - adverse effects ; Ventricular Function, Left</subject><ispartof>Circulation. Cardiovascular imaging, 2020-09, Vol.13 (9), p.e010599-e010599</ispartof><rights>American Heart Association, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4046-73ce5eab399a97d8e2ae9ff8b2461e4c7007f83855d3607ef5339a89ac1dd9b83</citedby><cites>FETCH-LOGICAL-c4046-73ce5eab399a97d8e2ae9ff8b2461e4c7007f83855d3607ef5339a89ac1dd9b83</cites><orcidid>0000-0003-3714-1256</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3685,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32873071$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pezel, Théo</creatorcontrib><creatorcontrib>Sanguineti, Francesca</creatorcontrib><creatorcontrib>Kinnel, Marine</creatorcontrib><creatorcontrib>Landon, Valentin</creatorcontrib><creatorcontrib>Bonnet, Guillaume</creatorcontrib><creatorcontrib>Garot, Philippe</creatorcontrib><creatorcontrib>Hovasse, Thomas</creatorcontrib><creatorcontrib>Unterseeh, Thierry</creatorcontrib><creatorcontrib>Champagne, Stéphane</creatorcontrib><creatorcontrib>Louvard, Yves</creatorcontrib><creatorcontrib>Claude Morice, Marie</creatorcontrib><creatorcontrib>Garot, Jérôme</creatorcontrib><title>Safety and Prognostic Value of Vasodilator Stress Cardiovascular Magnetic Resonance in Patients With Heart Failure and Reduced Ejection Fraction</title><title>Circulation. Cardiovascular imaging</title><addtitle>Circ Cardiovasc Imaging</addtitle><description>Patients with heart failure with reduced ejection fraction (HFrEF; heart failure with reduced left ventricular ejection fraction <40%) referred for stress cardiovascular magnetic resonance (CMR) may have a less optimal hemodynamic response to intravenous vasodilator. The aim was to assess the prognostic value of vasodilator stress perfusion CMR in patients with HFrEF.
Between 2008 and 2018, consecutive patients with HFrEF defined by left ventricular ejection fraction <40% prospectively referred for vasodilator stress perfusion CMR were followed for the occurrence of major adverse cardiovascular events (MACE), defined by cardiovascular death or nonfatal myocardial infarction. Univariable and multivariable Cox regressions were performed to determine the prognostic value of inducible ischemia or late gadolinium enhancement by CMR.
Of 1053 patients with HFrEF (65±11 years, median [interquartile range] left ventricular ejection fraction 38.7% [37.2-39.0]), 1018 (97%) completed the CMR protocol and 950 (93%) completed the follow-up (median [interquartile range], 5.6 [3.6-7.3] years); 117 experienced a MACE (12.3%). Stress CMR was well tolerated without any adverse events. Patients without ischemia or late gadolinium enhancement experienced a lower annual event rate of MACE (1.8%) than those with both ischemia and late gadolinium enhancement (12.0%;
<0.001). Using Kaplan-Meier analysis, inducible ischemia and late gadolinium enhancement were significantly associated with the occurrence of MACE (hazard ratio, 2.46 [95% CI, 1.69-3.60]; and hazard ratio, 2.92 [95% CI, 1.77-4.83], respectively, both
<0.001). In multivariable Cox regression, inducible ischemia was an independent predictor of a higher incidence of MACE (hazard ratio, 2.26 [95% CI, 1.52-3.35];
<0.001).
Stress CMR is safe and has a good discriminative prognostic value to predict the occurrence of MACE in patients with HFrEF.</description><subject>Aged</subject><subject>Contrast Media</subject><subject>Dipyridamole - administration & dosage</subject><subject>Dipyridamole - adverse effects</subject><subject>Female</subject><subject>Heart Failure - complications</subject><subject>Heart Failure - diagnostic imaging</subject><subject>Heart Failure - mortality</subject><subject>Heart Failure - physiopathology</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Longitudinal Studies</subject><subject>Magnetic Resonance Imaging, Cine - adverse effects</subject><subject>Male</subject><subject>Meglumine</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - etiology</subject><subject>Myocardial Perfusion Imaging - adverse effects</subject><subject>Organometallic Compounds</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Stroke Volume</subject><subject>Time Factors</subject><subject>Vasodilator Agents - administration & dosage</subject><subject>Vasodilator Agents - adverse effects</subject><subject>Ventricular Function, Left</subject><issn>1942-0080</issn><issn>1941-9651</issn><issn>1942-0080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkd1OGzEQha2qqFDaV0B-gU3H6_2xL9GKhEiEotCfy9XEniWmyxrZXhBv0UfuJqGIqzkX55yRvsPYmYCZEJX41izXzXJ1vlheL2YihxkIKLX-wE6ELvIMQMHHd_qYfY7xHqCSUKpP7FjmqpZQixP29xY7Si8cB8tvgr8bfEzO8F_Yj8R9N4noresx-cBvU6AYeYPBOv-E0Yw9Br7Cu4F2mTVFP-BgiLuB32ByNKTIf7u05ZeEIfE5un4MtP-1JjsasvzinkxyfuDzgHvxhR112Ef6-npP2c_5xY_mMrv6vlg251eZKaCosloaKgk3UmvUtVWUI-muU5u8qAQVpgaoOyVVWVpZQU1dKaVGpdEIa_VGyVNWHXpN8DEG6trH4B4wvLQC2h3i9h3idkLcHhBPwbND8HHcPJB9i_1nOhmKg-HZ94lC_NOPzxTaLWGftlOLlHWhVZZDDqABYFpot8w_HhSKtQ</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Pezel, Théo</creator><creator>Sanguineti, Francesca</creator><creator>Kinnel, Marine</creator><creator>Landon, Valentin</creator><creator>Bonnet, Guillaume</creator><creator>Garot, Philippe</creator><creator>Hovasse, Thomas</creator><creator>Unterseeh, Thierry</creator><creator>Champagne, Stéphane</creator><creator>Louvard, Yves</creator><creator>Claude Morice, Marie</creator><creator>Garot, Jérôme</creator><general>American Heart Association, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-3714-1256</orcidid></search><sort><creationdate>20200901</creationdate><title>Safety and Prognostic Value of Vasodilator Stress Cardiovascular Magnetic Resonance in Patients With Heart Failure and Reduced Ejection Fraction</title><author>Pezel, Théo ; Sanguineti, Francesca ; Kinnel, Marine ; Landon, Valentin ; Bonnet, Guillaume ; Garot, Philippe ; Hovasse, Thomas ; Unterseeh, Thierry ; Champagne, Stéphane ; Louvard, Yves ; Claude Morice, Marie ; Garot, Jérôme</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4046-73ce5eab399a97d8e2ae9ff8b2461e4c7007f83855d3607ef5339a89ac1dd9b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Contrast Media</topic><topic>Dipyridamole - administration & dosage</topic><topic>Dipyridamole - adverse effects</topic><topic>Female</topic><topic>Heart Failure - complications</topic><topic>Heart Failure - diagnostic imaging</topic><topic>Heart Failure - mortality</topic><topic>Heart Failure - physiopathology</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Longitudinal Studies</topic><topic>Magnetic Resonance Imaging, Cine - adverse effects</topic><topic>Male</topic><topic>Meglumine</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - etiology</topic><topic>Myocardial Perfusion Imaging - adverse effects</topic><topic>Organometallic Compounds</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Stroke Volume</topic><topic>Time Factors</topic><topic>Vasodilator Agents - administration & dosage</topic><topic>Vasodilator Agents - adverse effects</topic><topic>Ventricular Function, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pezel, Théo</creatorcontrib><creatorcontrib>Sanguineti, Francesca</creatorcontrib><creatorcontrib>Kinnel, Marine</creatorcontrib><creatorcontrib>Landon, Valentin</creatorcontrib><creatorcontrib>Bonnet, Guillaume</creatorcontrib><creatorcontrib>Garot, Philippe</creatorcontrib><creatorcontrib>Hovasse, Thomas</creatorcontrib><creatorcontrib>Unterseeh, Thierry</creatorcontrib><creatorcontrib>Champagne, Stéphane</creatorcontrib><creatorcontrib>Louvard, Yves</creatorcontrib><creatorcontrib>Claude Morice, Marie</creatorcontrib><creatorcontrib>Garot, Jérôme</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Circulation. Cardiovascular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pezel, Théo</au><au>Sanguineti, Francesca</au><au>Kinnel, Marine</au><au>Landon, Valentin</au><au>Bonnet, Guillaume</au><au>Garot, Philippe</au><au>Hovasse, Thomas</au><au>Unterseeh, Thierry</au><au>Champagne, Stéphane</au><au>Louvard, Yves</au><au>Claude Morice, Marie</au><au>Garot, Jérôme</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Prognostic Value of Vasodilator Stress Cardiovascular Magnetic Resonance in Patients With Heart Failure and Reduced Ejection Fraction</atitle><jtitle>Circulation. Cardiovascular imaging</jtitle><addtitle>Circ Cardiovasc Imaging</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>13</volume><issue>9</issue><spage>e010599</spage><epage>e010599</epage><pages>e010599-e010599</pages><issn>1942-0080</issn><issn>1941-9651</issn><eissn>1942-0080</eissn><abstract>Patients with heart failure with reduced ejection fraction (HFrEF; heart failure with reduced left ventricular ejection fraction <40%) referred for stress cardiovascular magnetic resonance (CMR) may have a less optimal hemodynamic response to intravenous vasodilator. The aim was to assess the prognostic value of vasodilator stress perfusion CMR in patients with HFrEF.
Between 2008 and 2018, consecutive patients with HFrEF defined by left ventricular ejection fraction <40% prospectively referred for vasodilator stress perfusion CMR were followed for the occurrence of major adverse cardiovascular events (MACE), defined by cardiovascular death or nonfatal myocardial infarction. Univariable and multivariable Cox regressions were performed to determine the prognostic value of inducible ischemia or late gadolinium enhancement by CMR.
Of 1053 patients with HFrEF (65±11 years, median [interquartile range] left ventricular ejection fraction 38.7% [37.2-39.0]), 1018 (97%) completed the CMR protocol and 950 (93%) completed the follow-up (median [interquartile range], 5.6 [3.6-7.3] years); 117 experienced a MACE (12.3%). Stress CMR was well tolerated without any adverse events. Patients without ischemia or late gadolinium enhancement experienced a lower annual event rate of MACE (1.8%) than those with both ischemia and late gadolinium enhancement (12.0%;
<0.001). Using Kaplan-Meier analysis, inducible ischemia and late gadolinium enhancement were significantly associated with the occurrence of MACE (hazard ratio, 2.46 [95% CI, 1.69-3.60]; and hazard ratio, 2.92 [95% CI, 1.77-4.83], respectively, both
<0.001). In multivariable Cox regression, inducible ischemia was an independent predictor of a higher incidence of MACE (hazard ratio, 2.26 [95% CI, 1.52-3.35];
<0.001).
Stress CMR is safe and has a good discriminative prognostic value to predict the occurrence of MACE in patients with HFrEF.</abstract><cop>United States</cop><pub>American Heart Association, Inc</pub><pmid>32873071</pmid><doi>10.1161/CIRCIMAGING.120.010599</doi><orcidid>https://orcid.org/0000-0003-3714-1256</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1942-0080 |
| ispartof | Circulation. Cardiovascular imaging, 2020-09, Vol.13 (9), p.e010599-e010599 |
| issn | 1942-0080 1941-9651 1942-0080 |
| language | eng |
| recordid | cdi_crossref_primary_10_1161_CIRCIMAGING_120_010599 |
| source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Aged Contrast Media Dipyridamole - administration & dosage Dipyridamole - adverse effects Female Heart Failure - complications Heart Failure - diagnostic imaging Heart Failure - mortality Heart Failure - physiopathology Humans Infusions, Intravenous Longitudinal Studies Magnetic Resonance Imaging, Cine - adverse effects Male Meglumine Middle Aged Myocardial Infarction - etiology Myocardial Perfusion Imaging - adverse effects Organometallic Compounds Predictive Value of Tests Prognosis Retrospective Studies Risk Assessment Risk Factors Stroke Volume Time Factors Vasodilator Agents - administration & dosage Vasodilator Agents - adverse effects Ventricular Function, Left |
| title | Safety and Prognostic Value of Vasodilator Stress Cardiovascular Magnetic Resonance in Patients With Heart Failure and Reduced Ejection Fraction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T01%3A13%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Prognostic%20Value%20of%20Vasodilator%20Stress%20Cardiovascular%20Magnetic%20Resonance%20in%20Patients%20With%20Heart%20Failure%20and%20Reduced%20Ejection%20Fraction&rft.jtitle=Circulation.%20Cardiovascular%20imaging&rft.au=Pezel,%20Th%C3%A9o&rft.date=2020-09-01&rft.volume=13&rft.issue=9&rft.spage=e010599&rft.epage=e010599&rft.pages=e010599-e010599&rft.issn=1942-0080&rft.eissn=1942-0080&rft_id=info:doi/10.1161/CIRCIMAGING.120.010599&rft_dat=%3Cpubmed_cross%3E32873071%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32873071&rfr_iscdi=true |